Nonetheless, the fact that more than half (4431/55 %) of the patients in our analysis had KI67 scores on two or more cores, with 83 % of these showing concordant KI67 status, should limit the impact of intra-tumour heterogeneity of KI67 scores on our findings. This evidence concerns the gene MKI67 and neoplasm.